GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Total Operating Expense

Xbrane Biopharma AB (OSTO:XBRANE) Total Operating Expense : kr398.4 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Total Operating Expense?

Xbrane Biopharma AB's Total Operating Expense for the three months ended in Dec. 2024 was kr92.8 Mil. Xbrane Biopharma AB's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr398.4 Mil.


Xbrane Biopharma AB Total Operating Expense Historical Data

The historical data trend for Xbrane Biopharma AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Total Operating Expense Chart

Xbrane Biopharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 223.74 187.17 231.19 357.55 398.42

Xbrane Biopharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.77 94.45 129.09 82.07 92.81

Xbrane Biopharma AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr398.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.

Xbrane Biopharma AB Headlines

No Headlines